Moleculin Biotech reports Q2 2026 financial results
Moleculin Biotech (MBRX) reports its second quarter 2026 financial results and highlights continued advancement of its pivotal MIRACLE trial.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.